MX2016001165A - Estabilizacion de polipeptidos que contienen fragmentos cristalizables. - Google Patents
Estabilizacion de polipeptidos que contienen fragmentos cristalizables.Info
- Publication number
- MX2016001165A MX2016001165A MX2016001165A MX2016001165A MX2016001165A MX 2016001165 A MX2016001165 A MX 2016001165A MX 2016001165 A MX2016001165 A MX 2016001165A MX 2016001165 A MX2016001165 A MX 2016001165A MX 2016001165 A MX2016001165 A MX 2016001165A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- stabilization
- polypeptides containing
- containing crystallizable
- crystallizable fragments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860800P | 2013-07-31 | 2013-07-31 | |
| PCT/US2014/048908 WO2015017548A2 (en) | 2013-07-31 | 2014-07-30 | Stabilization of fc-containing polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001165A true MX2016001165A (es) | 2016-06-29 |
Family
ID=52432568
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001165A MX2016001165A (es) | 2013-07-31 | 2014-07-30 | Estabilizacion de polipeptidos que contienen fragmentos cristalizables. |
| MX2022008013A MX2022008013A (es) | 2013-07-31 | 2016-01-27 | Estabilizacion de polipeptidos que contienen fragmentos cristalizables. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008013A MX2022008013A (es) | 2013-07-31 | 2016-01-27 | Estabilizacion de polipeptidos que contienen fragmentos cristalizables. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20160193295A1 (https=) |
| EP (1) | EP3027647A4 (https=) |
| JP (2) | JP2016526909A (https=) |
| KR (3) | KR20250152665A (https=) |
| CN (2) | CN121930334A (https=) |
| AU (3) | AU2014296215A1 (https=) |
| BR (1) | BR112016002219A2 (https=) |
| CA (1) | CA2919076C (https=) |
| CL (1) | CL2016000232A1 (https=) |
| EA (1) | EA035319B1 (https=) |
| HK (1) | HK1224203A1 (https=) |
| IL (1) | IL243690B (https=) |
| MX (2) | MX2016001165A (https=) |
| SG (1) | SG11201600734YA (https=) |
| WO (1) | WO2015017548A2 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| AU2015296640B2 (en) | 2014-07-30 | 2020-05-21 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| EP3701969A1 (en) * | 2014-10-31 | 2020-09-02 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| AU2016304794B2 (en) * | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| CN109475627B (zh) | 2016-05-26 | 2023-01-06 | 齐鲁普吉湾生物治疗公司 | 抗体混合物 |
| WO2018005226A2 (en) * | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| ES2973548T3 (es) * | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| WO2018144784A1 (en) * | 2017-02-01 | 2018-08-09 | Smet Pharmaceutical Inc. | MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES |
| AU2018295994B2 (en) * | 2017-07-07 | 2025-02-06 | Hanmi Pharm. Co., Ltd. | Novel therapeutic enzyme fusion protein and use thereof |
| US12297272B2 (en) * | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| CN107540748B (zh) * | 2017-09-15 | 2020-07-14 | 北京伟杰信生物科技有限公司 | 长效重组猪fsh融合蛋白及其制备方法与应用 |
| CN111511910B (zh) * | 2017-12-22 | 2024-11-08 | 韩美药品株式会社 | 具有新颖结构的治疗酶融合蛋白及其用途 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
| WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
| US10947278B2 (en) * | 2018-09-19 | 2021-03-16 | Bioapplications Inc. | Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof |
| KR102148405B1 (ko) * | 2018-09-19 | 2020-08-27 | 주식회사 바이오앱 | 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법 |
| KR102200773B1 (ko) * | 2018-09-19 | 2021-01-12 | 주식회사 바이오앱 | 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물 |
| US20220144916A1 (en) * | 2019-02-12 | 2022-05-12 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| MA56110A (fr) | 2019-06-07 | 2022-04-13 | Amgen Inc | Constructions de liaison bispécifiques à lieurs clivables de manière sélective |
| WO2021053556A1 (en) * | 2019-09-18 | 2021-03-25 | Novartis Ag | Nkg2d fusion proteins and uses thereof |
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| CA3159979A1 (en) * | 2019-12-11 | 2021-06-17 | Yeonchul Kim | Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation |
| US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| JP7481856B2 (ja) * | 2020-02-25 | 2024-05-13 | シスメックス株式会社 | 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 |
| CN111285936A (zh) * | 2020-03-11 | 2020-06-16 | 北京双赢科创生物科技有限公司 | 靶向肿瘤的酸性敏感纳米肽段及其应用 |
| TW202200615A (zh) | 2020-03-12 | 2022-01-01 | 美商安進公司 | 用於治療和預防患者的crs之方法 |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| WO2022032660A1 (zh) * | 2020-08-14 | 2022-02-17 | 武汉友微生物技术有限公司 | 新型冠状病毒rbd融合蛋白 |
| CN116194487B (zh) * | 2020-08-21 | 2026-03-17 | 命运抗体生成公司 | 由重链恒定区和轻链恒定区组成的γ恒定区（Cγ1）和ε恒定区（Cε2-4）融合的抗体片段及其用途 |
| CN114426974B (zh) * | 2020-10-29 | 2023-11-21 | 洛阳普泰生物技术有限公司 | 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段 |
| CA3196766A1 (en) * | 2020-11-02 | 2022-05-05 | Attralus, Inc. | Sap fc fusion proteins and methods of use |
| UY39507A (es) | 2020-11-06 | 2022-03-31 | Amgen Res Munich Gmbh | Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3 |
| US20220196651A1 (en) * | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US20240391971A1 (en) * | 2021-08-24 | 2024-11-28 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| CN116064562A (zh) * | 2022-10-28 | 2023-05-05 | 江南大学 | 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途 |
| CN119080948B (zh) * | 2023-04-17 | 2025-05-27 | 北京康乐卫士生物技术股份有限公司 | 带状疱疹病毒疫苗的嵌合抗原及其应用 |
| WO2025036564A1 (de) * | 2023-08-17 | 2025-02-20 | Gottfried Wilhelm Leibniz Universität Hannover (Luh) | Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern |
| WO2025162460A1 (zh) * | 2024-02-04 | 2025-08-07 | 南通壹宸生物医药科技有限公司 | 一种轭合化合物及其制备和应用 |
| CN118344462B (zh) * | 2024-06-18 | 2024-11-08 | 苏州易合医药有限公司 | 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品 |
| CN119613573B (zh) * | 2025-02-14 | 2025-05-30 | 浙江大学 | 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途 |
| CN119735654B (zh) * | 2025-02-27 | 2025-07-01 | 浙江海隆生物科技股份有限公司 | 一种牛副流感病毒的亚单位hn蛋白制备方法和应用 |
| CN120623322B (zh) * | 2025-08-14 | 2025-12-05 | 成都蓉生药业有限责任公司 | 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| ATE299938T1 (de) * | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2006028936A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| CA2631184A1 (en) * | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| MX340971B (es) * | 2009-11-23 | 2016-08-02 | Amgen Inc * | Fragmento cristalizable (fc) de anticuerpo monomerico. |
| EP2648752B1 (en) | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
-
2014
- 2014-07-30 CA CA2919076A patent/CA2919076C/en active Active
- 2014-07-30 AU AU2014296215A patent/AU2014296215A1/en not_active Abandoned
- 2014-07-30 IL IL243690A patent/IL243690B/en unknown
- 2014-07-30 KR KR1020257032842A patent/KR20250152665A/ko active Pending
- 2014-07-30 SG SG11201600734YA patent/SG11201600734YA/en unknown
- 2014-07-30 MX MX2016001165A patent/MX2016001165A/es unknown
- 2014-07-30 BR BR112016002219A patent/BR112016002219A2/pt not_active Application Discontinuation
- 2014-07-30 WO PCT/US2014/048908 patent/WO2015017548A2/en not_active Ceased
- 2014-07-30 EA EA201690299A patent/EA035319B1/ru not_active IP Right Cessation
- 2014-07-30 HK HK16112553.6A patent/HK1224203A1/zh unknown
- 2014-07-30 CN CN202610132063.5A patent/CN121930334A/zh active Pending
- 2014-07-30 US US14/909,431 patent/US20160193295A1/en not_active Abandoned
- 2014-07-30 KR KR1020167004786A patent/KR20160034404A/ko not_active Ceased
- 2014-07-30 KR KR1020237032656A patent/KR20230141929A/ko not_active Ceased
- 2014-07-30 CN CN201480046222.5A patent/CN105658664A/zh active Pending
- 2014-07-30 JP JP2016531860A patent/JP2016526909A/ja active Pending
- 2014-07-30 EP EP14832297.7A patent/EP3027647A4/en active Pending
-
2016
- 2016-01-27 MX MX2022008013A patent/MX2022008013A/es unknown
- 2016-01-28 CL CL2016000232A patent/CL2016000232A1/es unknown
-
2019
- 2019-03-08 US US16/297,494 patent/US20190192628A1/en active Pending
-
2020
- 2020-01-17 AU AU2020200329A patent/AU2020200329A1/en not_active Abandoned
- 2020-09-25 JP JP2020160475A patent/JP7344858B2/ja active Active
-
2022
- 2022-02-22 AU AU2022201204A patent/AU2022201204B2/en active Active
-
2025
- 2025-01-17 US US19/030,935 patent/US20250325631A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230141929A (ko) | 2023-10-10 |
| AU2020200329A1 (en) | 2020-02-06 |
| MX2022008013A (es) | 2022-07-27 |
| EA035319B1 (ru) | 2020-05-27 |
| BR112016002219A2 (pt) | 2017-09-12 |
| AU2022201204B2 (en) | 2025-01-02 |
| CL2016000232A1 (es) | 2016-09-02 |
| US20160193295A1 (en) | 2016-07-07 |
| EP3027647A4 (en) | 2017-01-04 |
| AU2014296215A1 (en) | 2016-02-11 |
| SG11201600734YA (en) | 2016-02-26 |
| JP2021019598A (ja) | 2021-02-18 |
| CN105658664A (zh) | 2016-06-08 |
| CA2919076A1 (en) | 2015-02-05 |
| IL243690B (en) | 2022-09-01 |
| US20250325631A1 (en) | 2025-10-23 |
| AU2022201204A1 (en) | 2022-03-17 |
| HK1224203A1 (zh) | 2017-08-18 |
| CN121930334A (zh) | 2026-04-28 |
| EP3027647A2 (en) | 2016-06-08 |
| WO2015017548A2 (en) | 2015-02-05 |
| KR20160034404A (ko) | 2016-03-29 |
| WO2015017548A3 (en) | 2015-11-05 |
| JP7344858B2 (ja) | 2023-09-14 |
| EA201690299A1 (ru) | 2016-11-30 |
| CA2919076C (en) | 2024-01-30 |
| JP2016526909A (ja) | 2016-09-08 |
| IL243690A0 (en) | 2016-04-21 |
| KR20250152665A (ko) | 2025-10-23 |
| US20190192628A1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016001165A (es) | Estabilizacion de polipeptidos que contienen fragmentos cristalizables. | |
| CO2017005639A2 (es) | Anticuerpos anti-miostatina, polipéptidos que contienen regiones fc variantes | |
| MX2023007211A (es) | Anticuerpos antimiostatina y metodos de uso. | |
| PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| MX2021013355A (es) | Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas. | |
| MX2018012539A (es) | Composiciones y métodos de células t receptoras de aloantígeno quimérico. | |
| MY205418A (en) | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments | |
| AR090706A1 (es) | Metodo para preparar peptidos tensioactivos | |
| CO2018002450A2 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
| MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| EA032960B1 (ru) | Антитела, содержащие химерные константные домены | |
| MX2017004664A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| PE20170503A1 (es) | Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso | |
| CO2022010422A2 (es) | Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo | |
| UY38542A (es) | Neoantígenos próstaticos, vacunas y composiciones farmacéuticas que los contienen | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| UY36678A (es) | Anticuerpos anti-fcrn. | |
| EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
| PE20151757A1 (es) | Anticuerpos anti-cd52 | |
| EP4028529A4 (en) | Fusion constructs to express biopharmaceutical polypeptides in cyanobacteria | |
| AR105689A1 (es) | Proteínas de fusión gitrl y sus usos | |
| AR090915A1 (es) | Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg | |
| AR095528A1 (es) | Polipéptidos de interleucina-22 (il-22) y proteínas de fusión de il-22 con fragmento de cadena pesada fc (il-22 fc) y métodos de uso | |
| AR106774A1 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
| NZ750009A (en) | Antibodies comprising chimeric constant domains |